<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo2405" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39011514</article-id><article-id pub-id-type="pmc">PMC11248715</article-id>
<article-id pub-id-type="doi">10.1002/deo2.405</article-id><article-id pub-id-type="publisher-id">DEO2405</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prophylactic effect of compression stockings for elevated D&#x02010;dimer levels following endoscopic submucosal dissection</article-title><alt-title alt-title-type="left-running-head">HARADA <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo2405-cr-0001" contrib-type="author"><name><surname>Harada</surname><given-names>Fumito</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="deo2405-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo2405-cr-0002" contrib-type="author" corresp="yes"><name><surname>Kodashima</surname><given-names>Shinya</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0007-0903-6279</contrib-id><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>kodashin0412@gmail.com</email></address></contrib><contrib id="deo2405-cr-0003" contrib-type="author"><name><surname>Ikusaka</surname><given-names>Ken</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0004" contrib-type="author"><name><surname>Aoki</surname><given-names>Naoaki</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0005" contrib-type="author"><name><surname>Shimizu</surname><given-names>Yuki</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0006" contrib-type="author"><name><surname>Honda</surname><given-names>Taku</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0007" contrib-type="author"><name><surname>Sakurai</surname><given-names>Miyoko</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0008" contrib-type="author"><name><surname>Maruyama</surname><given-names>Kyohei</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0009" contrib-type="author"><name><surname>Aoyagi</surname><given-names>Hitoshi</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0010" contrib-type="author"><name><surname>Isono</surname><given-names>Akari</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0011" contrib-type="author"><name><surname>Miura</surname><given-names>Ryo</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0012" contrib-type="author"><name><surname>Abe</surname><given-names>Koichiro</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0013" contrib-type="author"><name><surname>Arizumi</surname><given-names>Toshihiko</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0014" contrib-type="author"><name><surname>Asaoka</surname><given-names>Yoshinari</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0015" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Takatsugu</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo2405-cr-0016" contrib-type="author"><name><surname>Tanaka</surname><given-names>Atsushi</given-names></name><xref rid="deo2405-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo2405-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Medicine</named-content>
<institution>Teikyo University School of Medicine</institution>
<named-content content-type="country-part">Tokyo</named-content>
<country country="JP">Japan</country>
</aff><aff id="deo2405-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of the Gastroenterology</named-content>
<institution>Ageo Central General Hospital</institution>
<named-content content-type="country-part">Saitama</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Shinya Kodashima, Department of Medicine, Teikyo University School of Medicine, 2&#x02010;11&#x02010;1, Kaga, Itabashi&#x02010;ku, Tokyo 173&#x02013;8605, Japan.<break/> Email: <email>kodashin0412@gmail.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="111">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e405</elocation-id><history>
<date date-type="rev-recd"><day>16</day><month>6</month><year>2024</year></date>
<date date-type="received"><day>26</day><month>3</month><year>2024</year></date>
<date date-type="accepted"><day>27</day><month>6</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e405.pdf"/><abstract><title>Abstract</title><sec id="deo2405-sec-0010"><title>Objectives</title><p>A relationship between endoscopic submucosal dissection (ESD) and deep vein thrombosis has been recognized. We previously reported that a high corrected midazolam dose (total midazolam dose/initial dose of midazolam used to induce sedation) is related to elevated D&#x02010;dimer levels after ESD. In this study, the effect of compression stockings (CSs) in preventing thrombosis following ESD under sedation was evaluated by measuring D&#x02010;dimer levels before and after ESD.</p></sec><sec id="deo2405-sec-0020"><title>Methods</title><p>The participants were patients who underwent ESD for upper gastrointestinal tumors during the period between April 2018 and October 2022. Patients with pre&#x02010;ESD D&#x02010;dimer levels &#x02265;1.6 &#x000b5;g/m and patients with corrected midazolam doses &#x02264;3.0 were excluded. A retrospective investigation of the relationship between CS use and high post&#x02010;ESD D&#x02010;dimer levels (difference in D&#x02010;dimer levels &#x02265;1.0 &#x000b5;g/mL between before and after ESD) was conducted.</p></sec><sec id="deo2405-sec-0030"><title>Results</title><p>There were 27 patients in the non&#x02010;CS group (NCS) and 33 patients in the CS group. The number of patients with high post&#x02010;ESD D&#x02010;dimer levels was 13 (48.2%) in the non&#x02010;CS group and six (18.2%) in the CS group; the number in the CS group was significantly lower (<italic toggle="yes">p</italic> = 0.024). On logistic regression analysis, a relationship was seen between the wearing of CSs and a lower number of patients with high post&#x02010;ESD D&#x02010;dimer levels (odds ratio 0.24, 95% confidence interval 0.08&#x02013;0.79, <italic toggle="yes">p</italic> = 0.019).</p></sec><sec id="deo2405-sec-0040"><title>Conclusion</title><p>Wearing CSs was related to a lower risk of high post&#x02010;ESD D&#x02010;dimer levels. This result suggests that thrombus formation is a cause of elevated D&#x02010;dimer levels after ESD.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo2405-kwd-0001">compression stockings</kwd><kwd id="deo2405-kwd-0002">D&#x02010;dimer</kwd><kwd id="deo2405-kwd-0003">deep&#x02010;vein thrombosis</kwd><kwd id="deo2405-kwd-0004">endoscopic submucosal dissection</kwd><kwd id="deo2405-kwd-0005">sedative</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="7"/><word-count count="4027"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo2405-sec-0050"><title>INTRODUCTION</title><p>In Japan, endoscopic submucosal dissection (ESD) has become one of the major treatments for gastrointestinal tumors with a very low likelihood of metastasis.<xref rid="deo2405-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Compared with surgical operations, there is a lower incidence of early complications, shorter hospital stays, and a higher overall survival rate with ESD.<xref rid="deo2405-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo2405-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo2405-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> However, ESD procedures have a high level of difficulty and a high level of incidental risks such as perforation or bleeding.<xref rid="deo2405-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo2405-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> The possibility of long procedure times has also been noted as a problem<xref rid="deo2405-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo2405-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo2405-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>; therefore, the use of sedatives is almost essential in endoscopic procedures such as ESD that take a long time, and maintaining a moderate to higher level of sedation during the procedure is considered desirable.<xref rid="deo2405-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>
</p><p>It is well known that risk factors for deep vein thrombosis (DVT) include enhanced coagulability from surgical invasiveness, and being in the same position for a long period of time.<xref rid="deo2405-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The origin of the embolism in pulmonary thromboembolism, which could cause sudden death, is thought to be DVT in about 90% of cases,<xref rid="deo2405-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> making the prevention and treatment of DVT crucial. Kusunoki et&#x000a0;al. reported that asymptomatic DVT was seen in 10% of patients after ESD<xref rid="deo2405-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and it is thought that there may be a high risk of DVT in the post&#x02010;ESD period. However, there has been little discussion of specific risk factors associated with the occurrence of post&#x02010;ESD DVT.</p><p>We previously reported that D&#x02010;dimer levels are elevated in many patients after ESD for gastrointestinal tumors,<xref rid="deo2405-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> and that the corrected midazolam dose (total midazolam dose/initial dose of midazolam used to induce sedation) is related to elevated D&#x02010;dimer levels after ESD.<xref rid="deo2405-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> There are known to be individual differences in the sedative action of midazolam,<xref rid="deo2405-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo2405-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="deo2405-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo2405-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> and the dose of midazolam needs to be carefully determined while considering patient age, general condition, concurrent medications, and other factors. The corrected midazolam dose is the dose corrected for individual differences with this drug, as well as a value that shows how many multiples of the midazolam dose used before the start of the endoscopic procedure are administered over the entire treatment period. It is assumed to be proportional to the time during which the moderate or higher level of sedation recommended in guidelines has been maintained.<xref rid="deo2405-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Therefore, the duration of a moderate or higher level of sedation is conjectured to be related to elevated D&#x02010;dimer levels.</p><p>D&#x02010;dimer is used as a marker that reflects increased secondary fibrinolysis, and it is often used in diagnosing conditions such as disseminated intravascular coagulation and DVT.<xref rid="deo2405-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Although D&#x02010;dimer levels are also known to be elevated in conditions other than a thrombotic tendency, such as inflammatory diseases, malignant tumors, cirrhosis, pregnancy, and aging,<xref rid="deo2405-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> D&#x02010;dimer levels are widely used in clinical practice as an effective test to exclude disseminated intravascular coagulation&#x000a0;and DVT<xref rid="deo2405-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> since the existence of thrombi can be ruled out when D&#x02010;dimer levels are low. Investigations to date have not assessed the mechanisms that act in the elevation of D&#x02010;dimer levels after ESD. However, considering the relationship between the duration of moderate to higher levels of sedation and elevated D&#x02010;dimer levels in addition to reports that there is an increased risk of DVT occurring after ESD, it seems possible that elevated D&#x02010;dimer levels after ESD are due to a thrombotic tendency, and that there is a high possibility that this will cause DVT after ESD.<xref rid="deo2405-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Therefore, at our hospital it has been recommended since November 2020 that ESD patients with upper gastrointestinal tumors wear compression stockings (CSs) as a means of preventing DVT.</p><p>The effect of wearing CSs on preventing DVT after sedated ESD, based on measurements of D&#x02010;dimer before and after ESD, was assessed.</p></sec><sec id="deo2405-sec-0060"><title>SUBJECTS AND METHODS</title><sec id="deo2405-sec-0070"><title>Subjects</title><p>The participants in this study were patients who underwent ESD for upper gastrointestinal tumors (esophageal, gastric tumors) using intravenous anesthesia at our hospital during the period from April 2018 to October 2022, and whose D&#x02010;dimer (Sysmex Corporation) levels were measured before and after ESD. Pre&#x02010;ESD D&#x02010;dimer levels were measured at the time of hospital admission for ESD, and post&#x02010;ESD D&#x02010;dimer levels were measured in the morning of the day after ESD. Patients with pre&#x02010;ESD D&#x02010;dimer levels &#x02265;1.6 &#x000b5;g/mL, in whom the existence of thrombosis at the stage before ESD could not be ruled out, and patients with corrected midazolam doses &#x02264;3.0, who are thought to have a low risk of elevated D&#x02010;dimer levels after ESD, were excluded. Patients who did not wear CSs, mainly those before October 2020, were included as a non&#x02010;CS (NCS) group and patients who wore CSs starting in November 2020 were included as a CS group. The above study plan was approved by the ethics committee of Teikyo University School of Medicine (approval no. 20&#x02010;141&#x02010;2).</p></sec><sec id="deo2405-sec-0080"><title>ESD technique</title><p>All ESD procedures were performed by or under the guidance of an endoscopy instructor with at least 5 years of experience performing ESD. Sedatives and analgesics were administered during ESD as described below while monitoring the patient's level of consciousness, respiration, and hemodynamics. Compression stockings are put on the patients when they leave the ward on the day of ESD and are worn continuously until it is confirmed in the days after treatment that there are no procedure&#x02010;related complications.</p></sec><sec id="deo2405-sec-0090"><title>Sedative and analgesic regimens at our hospital</title><p>Midazolam was used in all patients as a sedative. Midazolam 0.5&#x02013;2 mg was intravenously administered before insertion of the endoscope, after which additional midazolam in amounts of 0.5&#x02013;1 mg each was added as needed while monitoring the level of sedation. When the level of sedation at which treatment could be started was attained, the endoscope was inserted at a stage determined by the endoscopist (the dose up to this point was taken to be the initial dose of midazolam). When sedation began to wear off during the procedure and an additional sedative was judged necessary, additional midazolam in amounts of 0.5&#x02013;1 mg each time was added at the discretion of the endoscopist. When sedation was not maintained even with the addition of midazolam, haloperidol was added together with the midazolam to maintain sedation.</p><p>For analgesia, either pentazocine hydrochloride or pethidine hydrochloride was used at the discretion of the endoscopist. Pentazocine hydrochloride 7.5 mg or pethidine hydrochloride 17.5 mg was administered intravenously as an initial dose. After the procedure was started, an additional analgesic was administered as needed at the discretion of the endoscopist.</p><p>After the entire procedure was completed and the endoscope was removed, 0.5 mg of the benzodiazepine antagonist Anexato was administered as needed and, upon confirming that the patient had awakened, the patient was moved out of the endoscopy unit. Patients rested in bed for 2 hours after the procedure. If there were no procedure&#x02010;related complications, they were then allowed to walk.</p></sec><sec id="deo2405-sec-0100"><title>Outcomes</title><p>The main outcome was to retrospectively demonstrate that wearing CSs suppresses increases in high D&#x02010;dimer levels after ESD.</p></sec><sec id="deo2405-sec-0110"><title>Statistical analysis</title><p>The statistical analysis was done using JMP 13.2.1 (SAS Institute Inc.). A difference in D&#x02010;dimer levels of &#x02265;1.0 &#x000b5;g/mL between before and after ESD was taken to be a high post&#x02010;ESD D&#x02010;dimer level, and Fisher's exact test and Welch's <italic toggle="yes">t</italic>&#x02010;test were used to compare demographic factors between the CS and the NCS group. In addition, a logistic regression analysis was performed with whether or not CSs were used, corrected midazolam dose, and procedure duration as explanatory variables, and the relationship between high post&#x02010;ESD D&#x02010;dimer levels and whether or not CSs were used was examined. <italic toggle="yes">p</italic> &#x0003c; 0.05 was taken to indicate a significant difference.</p></sec></sec><sec id="deo2405-sec-0120"><title>RESULTS</title><p>In the period from April 2018 to October 2022, 161 patients underwent ESD for upper gastrointestinal tumors using sedatives at our hospital, and their D&#x02010;dimer levels were measured before and after ESD. Of the 161 patients in this study, 105 patients wore CSs, and 66 did not. After excluding patients with pre&#x02010;ESD D&#x02010;dimer levels &#x02265;1.6 &#x000b5;g/mL (nine patients) and patients with a corrected midazolam dose &#x02264;3.0 (109 patients), there were 33 patients in the CS group and 27 patients in the NCS group (Figure&#x000a0;<xref rid="deo2405-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="FIGURE" id="deo2405-fig-0001"><label>FIGURE 1</label><caption><p>Flowchart of the study. ESD, endoscopic submucosal dissection.</p></caption><graphic xlink:href="DEO2-5-e405-g001" position="anchor" id="jats-graphic-1"/></fig><p>Table&#x000a0;<xref rid="deo2405-tbl-0001" ref-type="table">1</xref> compares the demographic factors between the CS group and the NCS group. The procedure duration was 202.6 &#x000b1; 67.6 and 150.6 &#x000b1; 49.8 min, respectively, significantly longer in the CS group (<italic toggle="yes">p</italic> = 0.002). The total midazolam dose was 8.0 &#x000b1; 1.8 and 6.8 &#x000b1; 2.6 mg, respectively, significantly higher in the CS group (<italic toggle="yes">p</italic> = 0.016), and the corrected midazolam dose was 4.4 &#x000b1; 1.2 and 4.7 &#x000b1; 1.1, respectively, which was not significantly different. The number of patients in whom pentazocine was used was 0 in the CS group and 10 in the NCS group, and the number of those in whom pethidine hydrochloride was used was 33 in the CS group and 18 in the NCS group. Both were significantly different (pentazocine use: <italic toggle="yes">p</italic> = 0.001, pethidine hydrochloride use: <italic toggle="yes">p</italic> = 0.001). The number of patients with high post&#x02010;ESD D&#x02010;dimer levels was six in the CS group and 13 in the NCS group; there were significantly fewer patients with high post&#x02010;ESD D&#x02010;dimer levels in the CS group (<italic toggle="yes">p</italic> = 0.024). None of the patients in both groups had clinically symptomatic DVT.</p><table-wrap position="float" id="deo2405-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Comparison of demographic factors between the compression stocking group and the non&#x02010;compression stocking group.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Compression stocking group (<italic toggle="yes">n</italic> = 33)</th><th align="left" rowspan="1" colspan="1">Non&#x02010;compression stocking group (<italic toggle="yes">n</italic> = 27)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex (male/female)</bold>
</td><td align="left" rowspan="1" colspan="1">27/6</td><td align="left" rowspan="1" colspan="1">18/9</td><td align="char" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age (years)</bold>
</td><td align="left" rowspan="1" colspan="1">70.8 &#x000b1; 8.71</td><td align="left" rowspan="1" colspan="1">74.4 &#x000b1; 9.76</td><td align="char" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ESD site (esophagus/stomach)</bold>
</td><td align="left" rowspan="1" colspan="1">10/23</td><td align="left" rowspan="1" colspan="1">9/18</td><td align="char" rowspan="1" colspan="1">0.801</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Thrombosis (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5</td><td align="char" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hypertension (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">15</td><td align="char" rowspan="1" colspan="1">0.693</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hyperlipidemia (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">8</td><td align="char" rowspan="1" colspan="1">0.454</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Diabetes mellitus (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">7</td><td align="char" rowspan="1" colspan="1">0.387</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Dialysis (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="char" rowspan="1" colspan="1">0.265</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Antiplatelet drug use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3</td><td align="char" rowspan="1" colspan="1">0.296</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Anticoagulant use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">2</td><td align="char" rowspan="1" colspan="1">0.814</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Procedure duration (min)</bold>
</td><td align="left" rowspan="1" colspan="1">202.6 &#x000b1; 67.6</td><td align="left" rowspan="1" colspan="1">150.6 &#x000b1; 49.8</td><td align="char" rowspan="1" colspan="1">0.002<xref rid="deo2405-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total midazolam dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">8.0 &#x000b1; 1.8</td><td align="left" rowspan="1" colspan="1">6.8 &#x000b1; 2.6</td><td align="char" rowspan="1" colspan="1">0.016<xref rid="deo2405-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Corrected midazolam dose</bold>
</td><td align="left" rowspan="1" colspan="1">4.4 &#x000b1; 1.2</td><td align="left" rowspan="1" colspan="1">4.7 &#x000b1; 1.1</td><td align="char" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pentazocine hydrochloride use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">10</td><td align="char" rowspan="1" colspan="1">0.001<xref rid="deo2405-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total pentazocine hydrochloride dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">&#x02010;</td><td align="left" rowspan="1" colspan="1">15.6 &#x000b1; 7.1</td><td align="char" rowspan="1" colspan="1">&#x02010;</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Pethidine hydrochloride use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">18</td><td align="char" rowspan="1" colspan="1">0.001<xref rid="deo2405-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total pethidine hydrochloride dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">56.2 &#x000b1; 20.4</td><td align="left" rowspan="1" colspan="1">54.4 &#x000b1; 23.9</td><td align="char" rowspan="1" colspan="1">0.941</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Haloperidol use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">13</td><td align="char" rowspan="1" colspan="1">0.271</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total haloperidol dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">5.0 &#x000b1; 1.9</td><td align="left" rowspan="1" colspan="1">5.4 &#x000b1; 2.5</td><td align="char" rowspan="1" colspan="1">0.722</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>High post&#x02010;ESD D&#x02010;dimer levels (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">6(18.2%)</td><td align="left" rowspan="1" colspan="1">13(48.2%)</td><td align="char" rowspan="1" colspan="1">0.024<xref rid="deo2405-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Symptomatic DVT (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0</td><td align="char" rowspan="1" colspan="1">&#x02010;</td></tr></tbody></table><table-wrap-foot><fn id="deo2405-tbl1-note-0001"><p>Continuous value variables are described as mean &#x000b1; standard deviation. ESD, Endoscopic submucosal dissection.</p></fn><fn id="deo2405-tbl1-note-0002"><label>
<sup>a</sup>
</label><p>: <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Table&#x000a0;<xref rid="deo2405-tbl-0002" ref-type="table">2</xref> shows the results of logistic regression analysis with wearing/not wearing CSs and corrected midazolam dose as explanatory variables. Wearing CSs was the only variable related to fewer patients with high post&#x02010;ESD D&#x02010;dimer levels (odds ratio 0.24, 95% confidence interval 0.08&#x02013;0.79, <italic toggle="yes">p</italic> = 0.019).</p><table-wrap position="float" id="deo2405-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Results of logistic regression analysis.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Change in D&#x02010;dimer from before to after ESD</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">&#x0003c;1.0 (<italic toggle="yes">n</italic> = 41)</th><th align="left" rowspan="1" colspan="1">&#x02265;1.0&#x03000;(<italic toggle="yes">n</italic> = 19)</th><th align="left" rowspan="1" colspan="1">Univariate</th><th align="left" rowspan="1" colspan="1">OR</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">Multivariate</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Wearing of compression stockings (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">27</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">0.013<xref rid="deo2405-tbl2-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">0.24</td><td align="left" rowspan="1" colspan="1">0.08&#x02013;0.79</td><td align="left" rowspan="1" colspan="1">0.019<xref rid="deo2405-tbl2-note-0001" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Procedure duration (min)</bold>
</td><td align="left" rowspan="1" colspan="1">179.9 &#x000b1; 66.5</td><td align="left" rowspan="1" colspan="1">177.7 &#x000b1; 64.0</td><td align="left" rowspan="1" colspan="1">0.949</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total midazolam dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">7.67 &#x000b1; 2.34</td><td align="left" rowspan="1" colspan="1">6.89 &#x000b1; 2.19</td><td align="left" rowspan="1" colspan="1">0.293</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Corrected midazolam dose</bold>
</td><td align="left" rowspan="1" colspan="1">4.45 &#x000b1; 1.19</td><td align="left" rowspan="1" colspan="1">4.67 &#x000b1; 1.11</td><td align="left" rowspan="1" colspan="1">0.267</td><td align="left" rowspan="1" colspan="1">0.91</td><td align="left" rowspan="1" colspan="1">0.55&#x02013;1.50</td><td align="left" rowspan="1" colspan="1">0.728</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total pethidine hydrochloride dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">55.2 &#x000b1; 18.4</td><td align="left" rowspan="1" colspan="1">59.3 &#x000b1; 23.4</td><td align="left" rowspan="1" colspan="1">0.554</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Total haloperidol dose (mg)</bold>
</td><td align="left" rowspan="1" colspan="1">5.13 &#x000b1; 2.06</td><td align="left" rowspan="1" colspan="1">5.18 &#x000b1; 2.29</td><td align="left" rowspan="1" colspan="1">0.917</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Thrombosis (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0.385</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hypertension (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">0.542</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Hyperlipidemia (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.873</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Diabetes mellitus (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0.672</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Dialysis (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0.139</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Antiplatelet drug use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">0.901</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Anticoagulant use (<italic toggle="yes">n</italic>)</bold>
</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0.112</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo2405-tbl2-note-0001"><label>
<sup>a</sup>
</label><p>: <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo2405-sec-0130"><title>DISCUSSION</title><p>Wearing CSs is one of the major means of DVT prophylaxis.<xref rid="deo2405-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="deo2405-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Compared with other DVT prophylactic methods, it has fewer complications and is simple and inexpensive. Thus, it is a widely used method. In this study, the use of CSs by patients undergoing ESD for upper gastrointestinal tumors was shown to be related to a lower risk of elevated D&#x02010;dimer levels after ESD.</p><p>In the present study, high post&#x02010;ESD D&#x02010;dimer levels were assessed with the difference in D&#x02010;dimer levels between before and after ESD set to &#x02265;1.0 &#x000b5;g/mL. The upper limit for a normal D&#x02010;dimer level is 1.0 &#x000b5;g/mL, and there are reports that, in patients prior to surgery, DVT can be ruled out with a D&#x02010;dimer cutoff value of 1.5 &#x000b5;g/mL.<xref rid="deo2405-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> On the other hand, the cutoff value for the postoperative D&#x02010;dimer level, which is related to the occurrence of DVT after ESD, is 1.9 &#x000b5;g/mL,<xref rid="deo2405-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> and a difference of 1.0 &#x000b5;g/mL in D&#x02010;dimer between before and after ESD is thought to significantly increase the possibility that DVT will occur due to a thrombotic tendency after ESD.</p><p>The corrected midazolam dose is the total dose of midazolam divided by the initial dose. It is a value corrected for the individual differences in the sedative effect of midazolam.<xref rid="deo2405-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> We previously reported that when the corrected midazolam dose increases, the risk of elevated D&#x02010;dimer after ESD also increases.<xref rid="deo2405-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> In the present study, with the purpose of focusing only on a high&#x02010;risk group for elevated D&#x02010;dimer levels after ESD, patients with a corrected midazolam dose &#x02264;3.0 were excluded since our previous study found that only 6.1% of cases with an elevated D&#x02010;dimer were present in cases with corrected midazolam dose &#x02264;3.0 and that the number of cases with elevated D&#x02010;dimer increased to 41% when corrected midazolam dose was greater than 3.0. In this investigation of a high&#x02010;risk group for elevated D&#x02010;dimer levels after ESD, high post&#x02010;ESD D&#x02010;dimer levels were seen in 48.2% of patients in the NCS group, with significantly fewer (18.2%) in the group that wore CSs as DVT prophylaxis. Compression stockings were judged to have an inhibitory effect on the elevation of D&#x02010;dimer levels after ESD.</p><p>To investigate whether new thrombus generation is inhibited by preventing the occurrence of DVT with CSs in the present study, it was necessary to exclude patients with a possible thrombotic tendency prior to ESD. Kawaguchi et&#x000a0;al. reported that preoperative DVT could be ruled out by taking a preoperative D&#x02010;dimer level of 1.5 &#x000b5;g/mL as a cutoff value in gynecological diseases.<xref rid="deo2405-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> In the present study, by excluding patients with pre&#x02010;ESD D&#x02010;dimer levels &#x02265;1.6 &#x000b5;g/mL, the investigation was conducted with patients limited to those in whom DVT was assumed to not be present before ESD. In previous studies, an elevated D&#x02010;dimer level was seen in patients with a high corrected midazolam level, that is, patients in whom the sedative effect was continued for a long time. From this, it was conjectured that an elevated D&#x02010;dimer level is caused by a postoperative thrombotic tendency from being in the same position for a long period. However, there are no reports of how frequently DVT occurs in patients with elevated D&#x02010;dimer levels, and in our past studies as well, the presence or absence of DVT was not evaluated in all patients. Thus, it has not been demonstrated that patients with elevated D&#x02010;dimer levels show a thrombotic tendency. As a result of having patients who were not thought to have a thrombotic tendency prior to ESD wear CSs for DVT prophylaxis in the present study, the elevation of D&#x02010;dimer levels after ESD was significantly inhibited compared with patients in whom DVT prophylaxis was not carried out. Therefore, the hypothesis that the cause of elevated D&#x02010;dimer levels after ESD is a thrombotic tendency is correct. The thrombotic tendency was inhibited by wearing CSs, and a prophylactic effect on DVT, which is reported to be seen in about 10% of patients after ESD,<xref rid="deo2405-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> was thought to have been obtained.</p><p>Since patients with a corrected midazolam dose &#x02264;3.0 were excluded from the present study, it may be thought that ESD patients in whom the endoscopic procedure was completed in a short time were excluded. In fact, the procedure duration in the CS and NCS groups was 202.6 &#x000b1; 67.6 and 150.6 &#x000b1; 49.8 min, respectively, which was long in both cases. The procedure duration tended to be significantly longer in the CS group, but since the CS group consisted of patients in November 2020 or later, the cause is thought to be that many of the endoscopists had changed and that the endoscopists&#x02019; skill in performing ESD differed in the two groups. In this investigation, in addition to the longer procedure duration in the CS group, a tendency for significantly larger total doses of midazolam was seen. Even so, there was no significant difference in the corrected midazolam dose, for which a relationship with postoperative elevated D&#x02010;dimer levels has been suggested. However, it is also thought that a difference in endoscopist background in the two groups may have affected not only procedure duration but also how midazolam was used in each group. A logistic regression analysis was conducted with wearing/not wearing CSs, corrected midazolam dose, and procedure duration as explanatory variables, and this multivariate analysis showed that only the variable of whether or not CSs were worn was related to a decrease in the number of patients with a difference in D&#x02010;dimer levels &#x02265;1.0 &#x000b5;g/mL between before and after ESD.</p><p>In endoscopic treatment, the use of both a sedative and an analgesic enhances the sedative effect; the possibility that the dose of sedative can be reduced has also been suggested.<xref rid="deo2405-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> In our hospital, pentazocine or pethidine hydrochloride is used as an analgesic, but which to use is left to the discretion of the endoscopist. As mentioned above, the background of endoscopists in the two groups differed in this study, and as a result the tendencies in selecting a sedative also differed. In a past report, the amount and type of sedative were not shown to be related to elevated D&#x02010;dimer levels after ESD,<xref rid="deo2405-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> but the number of patients in that study was small, and that assessment was insufficient. In the present study as well, since pethidine hydrochloride was used in all patients in the CS group, its influence cannot be sufficiently evaluated, and this remains a matter for further investigation.</p><p>Considering the results of the present study, DVT prophylaxis is thought to be desirable for patients whose corrected midazolam dose is high; that is, patients whose endoscopic treatment may require a long time under sedation. Since CSs are a DVT prophylactic method that is inexpensive and for which there are few contraindicated diseases,<xref rid="deo2405-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="deo2405-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> it is thought that DVT prophylaxis with CSs should be considered for endoscopic procedures performed under sedation.</p><p>This was a retrospective study with a small number of patients since only high&#x02010;risk patients were included. This and the slight differences in background between the two groups are limitations, and further investigation is considered necessary.</p></sec><sec sec-type="COI-statement" id="deo2405-sec-0140"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo2405-sec-0150"><title>ETHICS STATEMENT</title><p>This study was approved by the ethics committee of Teikyo University School of Medicine (approval no. 20&#x02010;141&#x02010;2).</p></sec></body><back><ref-list id="deo2405-bibl-0001"><title>REFERENCES</title><ref id="deo2405-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo2405-cit-0001">
<string-name>
<surname>Tanabe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ishido</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Matsumoto</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Long&#x02010;term outcomes of endoscopic submucosal dissection for early gastric cancer: A multicenter collaborative study</article-title>. <source>Gastric Cancer</source>
<year>2017</year>; <volume>20</volume> (Suppl <issue>1</issue>): <fpage>45</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">27807641</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="deo2405-cit-0002">
<string-name>
<surname>Park</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>DW</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Clinical safety of endoscopic submucosal dissection compared with surgery in elderly patients with early gastric cancer: A propensity&#x02010;matched analysis</article-title>. <source>Gastrointest Endosc</source>
<year>2014</year>; <volume>80</volume>: <fpage>599</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="pmid">24973177</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo2405-cit-0003">
<string-name>
<surname>Ryu</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>BG</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic submucosal dissection versus surgical resection for early gastric cancer: A retrospective multicenter study on immediate and long&#x02010;term outcome over 5 years</article-title>. <source>Surg Endosc</source>
<year>2016</year>; <volume>30</volume>: <fpage>5283</fpage>&#x02013;<lpage>5289</lpage>.<pub-id pub-id-type="pmid">27338583</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo2405-cit-0004">
<string-name>
<surname>Jeon</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>BE</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Long&#x02010;term outcome of endoscopic submucosal dissection is comparable to that of surgery for early gastric cancer: A propensity matched analysis</article-title>. <source>Gastric Cancer</source>
<year>2018</year>; <volume>21</volume>: <fpage>133</fpage>&#x02013;<lpage>143</lpage>.<pub-id pub-id-type="pmid">28397011</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo2405-cit-0005">
<string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Uraoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yamaguchi</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video)</article-title>. <source>Gastrointest Endosc</source>
<year>2010</year>; <volume>72</volume>: <fpage>1217</fpage>&#x02013;<lpage>1225</lpage>.<pub-id pub-id-type="pmid">21030017</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo2405-cit-0006">
<string-name>
<surname>Kim</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Cho</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KS</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Factors predictive of perforation during endoscopic submucosal dissection for the treatment of colorectal tumors</article-title>. <source>Endoscopy</source>
<year>2011</year>; <volume>43</volume>: <fpage>573</fpage>&#x02013;<lpage>578</lpage>.<pub-id pub-id-type="pmid">21448852</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo2405-cit-0007">
<string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukuzawa</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection</article-title>. <source>Surg Endosc</source>
<year>2010</year>; <volume>24</volume>: <fpage>343</fpage>&#x02013;<lpage>352</lpage>.<pub-id pub-id-type="pmid">19517168</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo2405-cit-0008">
<string-name>
<surname>Hotta</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Oyama</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shinohara</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Learning curve for endoscopic submucosal dissection of large colorectal tumors</article-title>. <source>Dig Endosc</source>
<year>2010</year>; <volume>22</volume>: <fpage>302</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">21175483</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="deo2405-cit-0009">
<string-name>
<surname>Gotoda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Akamatsu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Guidelines for sedation in gastroenterological endoscopy (second edition)</article-title>. <source>Dig Endosc</source>
<year>2021</year>; <volume>33</volume>: <fpage>21</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">33124106</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo2405-cit-0010">
<collab collab-type="authors">JCS Joint Working Group</collab>
. <article-title>Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009)</article-title>. <source>Circ J</source>
<year>2011</year>; <volume>75</volume>: <fpage>1258</fpage>&#x02013;<lpage>1281</lpage>.<pub-id pub-id-type="pmid">21441695</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo2405-cit-0011">
<string-name>
<surname>Kusunoki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Miyake</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shindo</surname>
<given-names>T</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The incidence of deep vein thrombosis in Japanese patients undergoing endoscopic submucosal dissection</article-title>. <source>Gastrointest Endosc</source>
<year>2011</year>; <volume>74</volume> (<issue>4</issue>): <fpage>798</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">21855867</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo2405-cit-0012">
<string-name>
<surname>Nakamura</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miki</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Safety of endoscopic submucosal dissection for gastrointestinal neoplasms: Risk of thrombosis</article-title>. <source>J Clin Physio</source>
<year>2020</year>; <volume>50</volume>: <fpage>87</fpage>&#x02013;<lpage>93</lpage>.</mixed-citation></ref><ref id="deo2405-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo2405-cit-0013">
<string-name>
<surname>Komatsuda</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kodashima</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ikusaka</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Risk factors for elevated D&#x02010;dimer levels in patients with gastrointestinal tumors treated with endoscopic submucosal dissection</article-title>. <source>J Clin Med</source>
<year>2023</year>; <volume>12</volume>: <fpage>5229</fpage>.<pub-id pub-id-type="pmid">37629270</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo2405-cit-0014">
<string-name>
<surname>Reves</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Fragen</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Vinik</surname>
<given-names>HR</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Midazolam: Pharmacology and uses</article-title>. <source>Anesthesiology</source>
<year>1985</year>; <volume>62</volume>: <fpage>310</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">3156545</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo2405-cit-0015">
<string-name>
<surname>Reed</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Rodarte</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Blumer</surname>
<given-names>JL</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>The single&#x02010;dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration</article-title>. <source>J Clin Pharmacol</source>
<year>2001</year>; <volume>41</volume>: <fpage>1359</fpage>&#x02013;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">11762564</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo2405-cit-0016">
<string-name>
<surname>Morrison</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Gibbons</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Whitehouse</surname>
<given-names>WP</given-names>
</string-name>. <article-title>High&#x02010;dose midazolam therapy for refractory status epilepticus in children</article-title>. <source>Int Care Med</source>
<year>2006</year>; <volume>32</volume>: <fpage>2070</fpage>&#x02013;<lpage>2076</lpage>.</mixed-citation></ref><ref id="deo2405-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo2405-cit-0017">
<string-name>
<surname>Tasker</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Midazolam for refractory status epilepticus in children: Higher dosing and more rapid and effective control</article-title>. <source>Int Care Med</source>
<year>2006</year>; <volume>32</volume>: <fpage>1935</fpage>&#x02013;<lpage>1936</lpage>.</mixed-citation></ref><ref id="deo2405-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo2405-cit-0018">
<string-name>
<surname>Elms</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bunce</surname>
<given-names>IH</given-names>
</string-name>, <string-name>
<surname>Bundesen</surname>
<given-names>PG</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Measurement of crosslinked fibrin degradation products&#x02212;An immunoassay using monoclonal antibodies</article-title>. <source>Thromb Haemost</source>
<year>1983</year>; <volume>50</volume>: <fpage>591</fpage>&#x02013;<lpage>594</lpage>.<pub-id pub-id-type="pmid">6356456</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo2405-cit-0019">
<string-name>
<surname>Rowbotham</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Carroll</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Whitaker</surname>
<given-names>AN</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Measurement of crosslinked fibrin derivatives&#x02212;Use in the diagnosis of venous thrombosis</article-title>. <source>Thromb Haemost</source>
<year>1987</year>; <volume>57</volume>: <fpage>59</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">3590082</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo2405-cit-0020">
<string-name>
<surname>Agu</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>D</given-names>
</string-name>. <article-title>Graduated compression stockings in the prevention of venous thromboembolism</article-title>. <source>Br J Surg</source>
<year>1999</year>; <volume>86</volume>: <fpage>992</fpage>&#x02013;<lpage>1004</lpage>.<pub-id pub-id-type="pmid">10460633</pub-id>
</mixed-citation></ref><ref id="deo2405-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo2405-cit-0021">
<string-name>
<surname>Kawaguchi</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Furukawa</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>H</given-names>
</string-name>. <article-title>Cut&#x02010;off value of D&#x02010;dimer for prediction of deep venous thrombosis before treatment in ovarian cancer</article-title>. <source>J Gynecol Oncol</source>
<year>2012</year>; <volume>23</volume>: <fpage>98</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">22523625</pub-id>
</mixed-citation></ref></ref-list></back></article>